{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:49:30Z","timestamp":1788871770253,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003495","name":"Hessisches Ministerium f\u00fcr Wissenschaft und Kunst (HMWK)","doi-asserted-by":"crossref","award":["III L 4\u2013518\/17.004"],"award-info":[{"award-number":["III L 4\u2013518\/17.004"]}],"id":[{"id":"10.13039\/501100003495","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"crossref","award":["P75\/08\/\/A62\/08"],"award-info":[{"award-number":["P75\/08\/\/A62\/08"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.jcyt.2014.01.003","type":"journal-article","created":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T20:30:50Z","timestamp":1393619450000},"page":"835-844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion"],"prefix":"10.1016","volume":"16","author":[{"given":"Eva","family":"Rettinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Kreyenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Merker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Ku\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Willasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried S.","family":"Wels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halvard","family":"Bonig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klingebiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2014.01.003_bib1","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/blood-2011-04-348805","article-title":"Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation","volume":"118","author":"Rettinger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.01.003_bib2","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1517\/14712590903005552","article-title":"Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation","volume":"9","author":"Sangiolo","year":"2009","journal-title":"Exp Opin Biol Ther"},{"key":"10.1016\/j.jcyt.2014.01.003_bib3","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.bbmt.2011.05.012","article-title":"Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"17","author":"Laport","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2014.01.003_bib4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2014.01.003_bib5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/intimm\/dxn042","article-title":"Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers","volume":"20","author":"Sangiolo","year":"2008","journal-title":"Int Immunol"},{"key":"10.1016\/j.jcyt.2014.01.003_bib6","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1182\/blood-2011-02-336321","article-title":"Dual-functional capability of CD3(+)CD56(+) CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity","volume":"118","author":"Pievani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.01.003_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse human lymphoma model to evaluate cytokine-induced killer-cells with potent antitumor cell-activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jcyt.2014.01.003_bib8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0167-5699(00)01735-7","article-title":"NKT cells: facts, functions and fallacies","volume":"21","author":"Godfrey","year":"2000","journal-title":"Immunol Today"},{"key":"10.1016\/j.jcyt.2014.01.003_bib9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.immunol.15.1.535","article-title":"Mouse CD1-specific NK1 T cells: development, specificity, and function","volume":"15","author":"Bendelac","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jcyt.2014.01.003_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12026-012-8285-7","article-title":"Investigation of NK cell function and their modulation in different malignancies","volume":"52","author":"Konjevic","year":"2012","journal-title":"Immunol Res"},{"key":"10.1016\/j.jcyt.2014.01.003_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1365-2141.2001.03164.x","article-title":"High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia","volume":"115","author":"Crazzolara","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2014.01.003_bib12","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1182\/blood.V99.11.4100","article-title":"The nonobese diabetic\/severe combined immunodeficient (NOD\/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse","volume":"99","author":"Lock","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.01.003_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.prp.2011.10.006","article-title":"Transplantation in the onco-hematology field: focus on the manipulation of alpha beta and gamma delta T cells","volume":"208","author":"Daniele","year":"2012","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jcyt.2014.01.003_bib14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1126\/science.1063916","article-title":"Regulation of cutaneous malignancy by gamma delta T cells","volume":"294","author":"Girardi","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2014.01.003_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/0008-5472.CAN-06-3069","article-title":"Perspectives of gamma delta T cells in tumor immunology","volume":"67","author":"Kabelitz","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2014.01.003_bib16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2008-12-196287","article-title":"The NKG2D ligand ULBP4 binds to TCR gamma 9\/delta 2 and induces cytotoxicity to tumor cells through both TCR gamma delta and NKG2D","volume":"114","author":"Kong","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.01.003_bib17","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood-2009-08-237123","article-title":"The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia\/lymphoma susceptibility to gamma delta T-cell cytotoxicity","volume":"115","author":"Lanca","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.01.003_bib18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12032-007-9004-4","article-title":"Anti-tumor cytotoxicity of gamma delta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma","volume":"25","author":"Saitoh","year":"2008","journal-title":"Med Oncol"},{"key":"10.1016\/j.jcyt.2014.01.003_bib19","first-page":"303","article-title":"Immunotherapy in pediatric hemato-oncology","volume":"7","author":"Lucchini","year":"2013","journal-title":"Hematology Education: the education program for the annual congress of the European Hematology Association"},{"key":"10.1016\/j.jcyt.2014.01.003_bib20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","article-title":"Gammadelta T cells for immune therapy of patients with lymphoid malignancies","volume":"102","author":"Wilhelm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.01.003_bib21","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","article-title":"Induction of gamma delta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo","volume":"102","author":"Dieli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.01.003_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1084\/jem.20030235","article-title":"Differentiation of effector\/memory V delta 2 T cells and migratory routes in lymph nodes or inflammatory sites","volume":"198","author":"Dieli","year":"2003","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jcyt.2014.01.003_bib23","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1158\/1078-0432.CCR-06-2602","article-title":"The graft content of donor T cells expressing gamma delta TCR+ and CD4(+)foxp3(+) predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors","volume":"13","author":"Pabst","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2014.01.003_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/14653249.2011.613931","article-title":"The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells","volume":"14","author":"Rettinger","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2014.01.003_bib25","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-SCID IL2R gamma(null) mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jcyt.2014.01.003_bib26","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-06-092817","article-title":"In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity","volume":"112","author":"Nishimura","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.01.003_bib27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fonc.2012.00032","article-title":"Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models","volume":"2","author":"Rettinger","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2014.01.003_bib28","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3324\/haematol.2009.019885","article-title":"Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation","volume":"95","author":"Kuci","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2014.01.003_bib29","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3324\/haematol.2009.015065","article-title":"CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties","volume":"95","author":"Kuci","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2014.01.003_bib30","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jss.2013.02.025","article-title":"Distribution of several activating and inhibitory receptors on CD3(\u2013)CD56(+) NK cells in regional lymph nodes of melanoma patients","volume":"183","author":"Vuleti\u0107","year":"2013","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.jcyt.2014.01.003_bib31","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.exphem.2011.06.005","article-title":"Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy","volume":"39","author":"Niam","year":"2011","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jcyt.2014.01.003_bib32","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.exphem.2009.01.010","article-title":"Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes","volume":"37","author":"Franceschetti","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jcyt.2014.01.003_bib33","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.V86.9.3493.bloodjournal8693493","article-title":"Two pathways of exocytosis of cytoplasmic granule contents and target-cell killing by cytokine-induced Cd3(+)Cd56(+) killer-cells","volume":"86","author":"Mehta","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.01.003_bib34","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1182\/blood.V92.9.3318","article-title":"Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: and in vivo efficacy in severe combined immunodeficiency disease mice","volume":"92","author":"Hoyle","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2014.01.003_bib35","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.4049\/jimmunol.153.4.1687","article-title":"A\u00a0novel population of expanded human Cd3+Cd56+ cells derived from T-cells with potent in-vivo antitumor-activity in mice with severe combined immunodeficiency","volume":"153","author":"Lu","year":"1994","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jcyt.2014.01.003_bib36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2567.2008.02910.x","article-title":"Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell","volume":"126","author":"Linn","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jcyt.2014.01.003_bib37","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00277-011-1156-9","article-title":"Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer\/natural killer cells in K562 NOD\/SCID mice","volume":"90","author":"Li","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2014.01.003_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1015415928521","article-title":"Studies of ex vivo activated and expanded CD8(+) NK-T cells in humans and mice","volume":"22","author":"Verneris","year":"2002","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jcyt.2014.01.003_bib39","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/bmt.2013.19","article-title":"Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation","volume":"48","author":"Rettinger","year":"2013","journal-title":"Bone Marrow Transplant"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324914000231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324914000231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:20:09Z","timestamp":1761430809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324914000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1465324914000231"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2014.01.003","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2014.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}